Metformin and Esomeprazole in Treatment of Early Onset Preeclampsia

NCT03717701 NA UNKNOWN

Preeclampsia is globally responsible for tens of thousands of maternal and neonatal deaths each year. Currently, there are no medical therapies to halt disease progression and expectant management and delivery remain the mainstay of treatment. An important step in the pathogenesis of preeclampsia is a poor placental invasion and the subsequent release of the anti-angiogenic factors soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng)into the maternal circulation. Given metformin and esomeprazole successfully mitigate key pathogenic features of preeclampsia, the investigator will study whether combining low-doses of metformin and esomeprazole may be additive or synergistic (or neither) in reducing sFlt-1 and sEng secretion, and mitigating endothelial dysfunction, compared to placebo.

Details

Lead sponsor	Aswan University Hospital
Phase	NA
Status	UNKNOWN
Enrolment	120
Start date	Sat Dec 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pre-Eclampsia

Interventions

• metformin
• esomeprazole
• Placebo

Countries

Egypt